Material Event (Form 8-K)

Item 8.01

Other Events.

On April 14, 2025, Verve Therapeutics, Inc. (the "Company") announced positive initial safety and efficacy data from its ongoing Heart-2 Phase 1b clinical trial of VERVE-102 in adult patients with heterozygous familial hypercholesterolemia ("HeFH") and/or premature coronary artery disease ("CAD"). VERVE-102 is a novel, in vivo, investigational base editing medicine designed to be a single-course treatment that permanently turns off the PCSK9gene in the liver and durably reduces disease-driving low-density lipoprotein cholesterol ("LDL-C"). VERVE-102 consists of an adenine base editor and a guide RNA ("gRNA") targeting the PCSK9gene. Both are encapsulated in a lipid nanoparticle ("LNP") and administered as a single intravenous infusion over two to four hours. VERVE-102 uses the Company's proprietary GalNAc-LNP delivery technology, which is designed to allow the LNP to access liver cells using either the low-density lipoprotein receptor or the asialoglycoprotein receptor.

The Heart-2 clinical trial is an open-label Phase 1b clinical trial designed to evaluate the safety and tolerability of VERVE-102 administration in adult patients with HeFH and/or premature CAD who require additional lowering of LDL-C. The trial is a single-ascending dose study and endpoints include pharmacokinetics and changes in blood LDL-C and PCSK9 protein levels. HeFH is diagnosed based on high LDL-C levels, a personal or family history of atherosclerotic cardiovascular disease, physical exam features, and/or mutations identified in certain genes. Premature CAD is defined as evidence of CAD (heart attack, coronary revascularization procedure or coronary atherosclerosis on imaging) occurring in men aged ≤ 55 years old or women aged ≤ 65 years old. The initial safety and efficacy data reported on April 14, 2025 are from 14 participants from the first three dose cohorts (weight-based cohorts of 0.3 mg/kg, 0.45 mg/kg, and 0.6 mg/kg) with at least 28 days of follow-up for each participant as of a data cutoff date of March 13, 2025.

Initial data showed that VERVE-102 has been well-tolerated, with no treatment-related serious adverse events, no dose-limiting toxicities, and no cardiovascular events observed. Across all 14 participants, there was one Grade 2 infusion related reaction which involved transient symptoms that resolved with acetaminophen. No clinically significant changes or dose-dependent trends in alanine aminotransferase, aspartate aminotransferase, bilirubin, or platelets were observed at any dose level.

Following a single infusion of VERVE-102, dose-dependent reductions in two pharmacodynamic measures were observed. Mean blood LDL-C and PCSK9 protein reductions from baseline, using a time-averaged percent change from day 28 through the last available follow-up, were as follows:

•

Cohort 1; 0.3 mg/kg (n=4): LDL-C reduction was 21% and PCSK9 reduction was 46%.

•

Cohort 2; 0.45 mg/kg (n=6): LDL-C reduction was 41% and PCSK9 reduction was 53%.

•

Cohort 3; 0.6 mg/kg (n=4): LDL-C reduction was 53% and PCSK9 reduction was 60%.

Among the 14 participants, a maximum LDL-C reduction of 69% was achieved in a participant in the 0.6 mg/kg cohort.

For LNP-delivered in vivogene editing medicines, total RNA dose administered is emerging as a key driver of pharmacodynamics. As such, the Company also evaluated the Heart-2 pharmacodynamic data by total RNA dose. The analysis includes the 14 participants in the Heart-2 clinical trial grouped into three ranges of total RNA dose administered: < 25 mg (n=4), 25 - < 50 mg (n=7), and 50 - < 60 mg (n=3).

Mean LDL-C reductions from baseline, using a time-averaged percent change from day 28 through the last available follow-up, were as follows:

VERVE-102 total RNA dose range		< 25 mg		25 - < 50 mg		50 - < 60 mg
Participants, n		4		7		3
Mean total RNA dose		20 mg		37 mg		55 mg
Mean LDL-C % reduction from baseline		-21%		-41%		-59%

Across all 14 participants, VERVE-102 demonstrated a strong dose-dependent response between the amount of total RNA administered and LDL-C reductions. Three participants received a total RNA dose between 50 and 60 mg, with an average dose received of 55 mg of total RNA. In this dose group, VERVE-102 demonstrated a time-averaged LDL-C mean reduction of 59%. Each of the three participants who received a dose > 50 mg achieved a > 50% time-averaged reduction of LDL-C from baseline.

The Heart-2 trial is enrolling participants in the fourth dose cohort of 0.7 mg/kg in the United Kingdom, Canada, Israel, Australia, and New Zealand. As of April 7, 2025, two participants have been dosed in this cohort and the early laboratory and clinical safety profile has been in line with that observed in the first three dose cohorts. The Company expects to announce the final data from the dose escalation portion of the Heart-2 trial, including durability data, in the second half of 2025.

The Company plans to dose the first patient in the Phase 2 clinical trial of VERVE-102 in the second half of 2025, subject to regulatory clearance. With the recent clearance by the U.S. Food and Drug Administration (the "FDA") of the investigational new drug application for VERVE-102, the Company expects to enroll patients at U.S. trial sites in the Phase 2 clinical trial. The Company expects its current capital position to be sufficient to fund its operations into mid-2027, which includes the completion of the Phase 2 clinical trial. In addition, the FDA granted Fast Track designation for VERVE-102for the treatment of patient groups with hyperlipidemia and high lifetime cardiovascular risk to reduce LDL-C.

The Company plans to wind-down development activities related to VERVE-101, including discontinuation of the Heart-1 Phase 1b clinical trial of VERVE-101. Participants enrolled in the long-term follow-up study of VERVE-101 will continue to be monitored.

Under the PCSK9 program collaboration agreement with the Company, Eli Lilly and Company ("Lilly") holds the right to opt-in to share worldwide development expenses (33% contributed by Lilly) and to jointly commercialize and share profits and expenses related to commercialization in the United States on a 50/50 basis. The Company retains control of the development and commercialization of all collaboration products in the United States, and the Company holds all product rights outside the United States. The Company expects to deliver the opt-in package for the PCSK9 program and receive a decision from Lilly in the second half of 2025.